Penfigoide ampolloso y vacuna COVID-19

Pérez-López, Israel; Moyano-Bueno, David; Ruiz‐Villaverde, Ricardo

doi:10.1016/j.medcli.2021.05.005

Cited by 21 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason for exclusion included no discussion of vesicular, papulovesicular, or bullous reactions ( n = 167). Twenty-seven 12 , 13 , 17 - 41 of the 36 articles described nonspecific vesicular, papulovesicular, or bullous reactions, compared to eleven 18 , 24 , 42 - 50 discussing vesicular eruptions in concordance with new-onset or reactivation of the herpes zoster virus. During the screening process, a total of 66 articles discussing other cutaneous manifestations were retrieved from the full-text screening to extract data in tabular formats and were discussed in our narrative review.…”

Section: Resultsmentioning

confidence: 99%

“…Bullous reactions after the Pfizer vaccine have mostly been described in 13 studies including 12 case reports or case series and 1 registry study, 4 of which were confirmed cases of bullous pemphigoid. 13 , 18 , 23 , 27 , 28 , 31 - 38 Upon combining the patients receiving the Pfizer vaccines, 13.5% of 178 cases developed bullous eruptions after the first dose reported in 12 studies compared to 13.5% of 156 cases after the second dose reported in 8 studies. Four cases had reactions after both the first and second vaccines and 2 cases had ongoing or unresolved lesions when receiving the second dose, which persisted after the second dose as well.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review

Mahmood

Cyr

et al. 2023

J Cutan Med Surg

View full text Add to dashboard Cite

As coronavirus disease (COVID-19) vaccines continue to be administered, dermatologists play a critical role in recognizing and treating the cutaneous manifestations (CM) associated with the vaccines. Adverse cutaneous reactions of COVID-19 vaccines reported in the literature range from common urticarial to rare vesiculobullous reactions. In this study, we performed a (1) scoping review to assess the occurrences of vesicular, papulovesicular, and bullous CMs of COVID-19 vaccines and their respective treatments, and (2) a narrative review discussing other common and uncommon CMs of COVID-19 vaccines. Thirty-six articles were included in the scoping review, and 66 articles in the narrative review. We found that vesicular, papulovesicular, and bullous lesions are infrequent, reported mostly after the first dose of Moderna or Pfizer vaccines. Eleven of the 36 studies reported vesicular reactions consistent with activation or reactivation of the herpes zoster virus. Most vesicular and bullous lesions were self-limited or treated with topical corticosteroids. Other CMs included injection-site, urticarial or morbilliform reactions, vasculitis, toxic epidermal necrolysis, and flaring of or new-onset skin diseases such as psoriasis. Treatments for CMs included topical or oral corticosteroids, antihistamines, or no treatment in self-limited cases. Although most CMs are benign and treatable, the data on the effect of systemic corticosteroids and immunosuppressive therapies on the immunogenicity of COVID-19 vaccines is limited. Some studies report reduced immunogenicity of the vaccines after high-dose corticosteroids use. Physicians may consult local guidelines where available when recommending COVID-19 vaccines to immunosuppressed patients, and when using corticosteroids to manage the CMs of COVID-19 vaccines.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review

Mahmood

Cyr

et al. 2023

J Cutan Med Surg

View full text Add to dashboard Cite

show abstract

“…Hence, COVID-19 vaccine may induce a large immunologic response in immunologically susceptible individuals and subsequent antibody production. 6 BP induced by vaccination against rabies 7 influenza, pneumococcus, tetanus, diphtheria 8 and pertussis has been reported in the literature, indicating that vaccination can trigger the disease. Therefore, our experience may further suggest a hyperimmune reaction induced in genetically predisposed individuals or a cross-reaction of vaccine antigens with BP antigens, supporting the possible worsening of BP manifestations to COVID-19 vaccination.…”

mentioning

confidence: 96%